Compare NE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NE | ABVX |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | France |
| Employees | 4500 | 69 |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.2B |
| IPO Year | N/A | N/A |
| Metric | NE | ABVX |
|---|---|---|
| Price | $41.93 | $98.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $46.00 | ★ $131.31 |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 04-26-2026 | 03-23-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.14 |
| Revenue Next Year | $9.18 | $4,132.27 |
| P/E Ratio | $32.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.24 | $7.41 |
| 52 Week High | $54.98 | $148.83 |
| Indicator | NE | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 28.25 | 42.21 |
| Support Level | $27.78 | $87.60 |
| Resistance Level | $47.36 | $98.59 |
| Average True Range (ATR) | 1.50 | 6.59 |
| MACD | -0.49 | 0.04 |
| Stochastic Oscillator | 1.57 | 23.57 |
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and on deploying its drilling rigs in oil and gas basins around the world. The mobile offshore drilling units comprising the offshore rig fleet operate in international markets for contract drilling services and are often redeployed to different regions due to changing customer demand, which consists mainly of large, integrated, independent, and government-owned or controlled oil and gas companies throughout the world.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.